Is it a sell? Why is Morgans saying 'avoid' the Magellan (ASX:MFG) share price?

Leading brokers including Morgans give their view.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in fund manager Magellan Financial Group Ltd (ASX: MFG) were rangebound today and trade more than 4% higher at $20.56.

Magellan shares have pared long-term gains and now trade deep in the red across all relevant time frames after a string of headwinds has plagued its manager performance lately.

What do the experts think? Let's take a look at what analysts from leading investment firms are saying on the outlook for Magellan investors.

man thinking about whether to invest in bitcoin

Image source: Getty Images

What is Morgans saying about Magellan's outlook?

Morgans takes immediate note of UK based wealth management giant St James Place withdrawing its investment mandate from Magellan's book, and also takes a balanced view of its outcome.

On the one hand, it notes the contagion risk for its flagship fund, however also notes that the withdrawal makes Magellan's headline valuation look attractive.

Despite the optimism, however, Morgans remains unconfident on Magellan's funds under management and the stability of its fees, saying that "medium term earnings risk are still present" in that regard.

Moreover, the risk of contagion or loss of another large institutional investor from St James Place's exit is a real risk which investors must consider, Morgans says. This could impact retail outflows and force retail fee reductions, Morgans says.

In the end, the broker states that "we would avoid the stock until there is more certainty in the funds under management base and earnings outlook".

It is neutral on the shares and values Magellan at $24.15 per share, in line with Jarden who have Magellan as a sell at $24.

Is Magellan a sell?

Meanwhile, Morgan Stanley says that Magellan's bear case is finally playing out after St James Place's exit, causing the broker to slash its price target by 40% to $17.50.

Morgan Stanley notes that a particular institutional client accounted for around 12% of Magellan's annual revenues, and the broker is now worried about the lumpy revenues from other large clients.

It too recognises a threat to Magellan's retail fees, which already sit at the highest amongst its peer group, and reckons a cut to Magellan's 90%+ payout ratio is likely on the horizon. Morgan Stanley thinks Magellan is a sell.

UBS is also bearish, noting that St James Place's withdrawal is a sign for broader concern. UBS notes that the institutional wealth manager accounted for 16% of Magellan's funds under management, which could risk a follow on event.

UBS says that "with the stock down 33% on the news, investors are righty, in our view, factoring in broader contagion of institutional outflows".

The investment bank itself forecasts $23 billion of net outflows over the next 2-3 years in its own modelling, according to the note.

UBS rates Magellan as a sell with these risks in mind on a valuation of just $17 per share.

Magellan share price summary

Magellan's share price is down 64% in the past 12 months after falling another 63% this year to date. Over the past month is has extended losses and has plunged 43%, and has tanked more than 32% in the last week.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »

Wlorker on a laptop on top of solar panels.
Broker Notes

Up 8%, should I buy the rebound in Origin Energy shares today?

A leading analyst provides his forecast for Origin Energy’s rebounding shares.

Read more »

A woman stands in a field and raises her arms to welcome a golden sunset.
Gold

4 ASX 200 gold shares to buy: Experts

Experts explain their buy ratings following these miners' June quarter reports.

Read more »

Three balls at various places on a cycle.
Broker Notes

6 ASX uranium shares to buy ahead of yellow cake rising to US$200 per pound: experts

This broker tips 83% to 295% upside over 12 months for its 6 top ASX uranium share picks.

Read more »

A hipster-looking man with bushy beard and multiple arm tattoos sits on the floor against a sofa reading a tablet with his hand on his chin as though he is deep in thought.
Broker Notes

Buy, hold, sell: Capstone Copper, Lindsay Australia, Woodside shares

Let's take a look at three fresh buy, hold, and sell calls from the experts. 

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 23% and 58%, should I buy TechnologyOne and Xero shares now?

A leading expert provides his forecasts for TechnologyOne and Xero shares.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands.
Broker Notes

Buy, hold, sell: Ramsay Healthcare, Xero, Electro Optic Systems shares

Let's take a look at three fresh buy, hold, and sell calls from the experts. 

Read more »